REGN Stock Cash Flow Statements

Regeneron Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Regeneron Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-03-31	2008-09-30	2008-06-30	2008-03-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30

cash flows from operating activities:
net income	1,391,600,000	808,700,000	917,700,000	1,340,600,000	1,432,300,000	722,000,000	1,159,600,000	1,007,800,000	968,400,000	817,800,000	1,197,100,000	1,315,700,000	852,100,000	973,500,000	2,229,000,000	1,632,200,000	3,098,900,000	1,115,200,000	1,149,200,000	842,100,000	897,300,000	624,600,000	792,000,000	669,600,000	193,100,000	461,100,000	820,353,000	594,655,000	551,412,000	477,980,000	173,519,000	388,317,000	387,744,000	248,931,000	253,115,000	264,804,000	211,867,000	165,736,000	154,994,000	210,398,000	194,643,000	76,021,000	110,176,000	79,720,000	92,735,000	65,443,000	96,806,000	141,306,000	87,376,000	98,874,000	470,407,000	191,468,000	76,743,000	11,651,000	-62,365,000	-62,505,000	-43,447,000	-14,597,000	-33,875,000	-25,474,000	-30,522,000	-17,481	-21,115,000	-18,459,000	-11,618,000	-35,838,000	-26,774,000	-29,917,000	-30,971,000	-27,410,000	-23,576,000	-20,380,000	-29,672,000	-34,652,000	-26,999,000	-4,123,000	2,792,000	-11,076,000	-14,549,000	64,532,000	-19,377,000	-29,235,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	135,100,000	126,900,000	126,400,000	121,700,000	120,700,000	114,100,000	113,000,000	105,400,000	103,100,000	99,500,000	100,100,000	92,600,000	74,400,000	74,300,000	74,500,000	73,200,000	71,100,000	67,400,000	61,700,000	59,300,000	58,800,000	56,100,000	54,300,000	52,900,000	52,100,000	51,000,000	42,759,000	35,441,000	33,642,000	36,358,000	34,507,000	37,719,000	35,126,000	38,115,000	28,900,000	27,839,000	25,029,000	22,977,000	22,910,000	20,674,000	15,298,000	16,027,000	14,135,000	14,005,000	13,016,000	11,530,000	11,292,000	10,803,000	9,702,000	9,407,000	9,778,000	9,329,000	9,417,000	8,416,000	8,276,000	7,902,000	6,978,000	6,086,000	4,894,000	4,524,000	4,183,000	2,724	2,774,000	2,941,000	2,946,000	2,859,000	2,874,000	2,855,000	3,396,000	3,708,000	3,690,000	3,798,000	3,880,000	3,935,000	3,831,000	3,858,000		3,876,000	3,797,000	3,773,000
stock-based compensation expense	251,700,000	255,700,000	304,400,000	225,100,000	223,200,000	230,100,000	240,400,000	203,900,000	202,000,000	238,700,000	232,000,000	166,300,000	159,800,000	166,900,000
gains on marketable and other securities															137,600,000	29,300,000
other	-7,400,000	-10,300,000	0																								0																																										0	0
deferred income taxes	-135,200,000	-139,100,000	-280,200,000	-168,600,000	-118,100,000	-190,400,000	-286,300,000	-125,700,000	-209,300,000	-216,500,000
changes in assets and liabilities:
decrease (increase) in accounts receivable											219,600,000	-386,900,000	-322,400,000	1,197,500,000																																									6,117,000	3,592,000	4,956,000																-25,985,000	6,294,000	-6,459,000	32,731,000
increase in inventories	-42,500,000	-152,300,000	-117,700,000	-164,400,000	-181,800,000	-155,800,000	-47,300,000	-77,200,000	-100,400,000	-46,800,000	-144,300,000	-223,500,000	-240,100,000	-88,600,000	-163,700,000	-109,100,000	31,300,000	-252,800,000	-127,000,000	-169,000,000	-162,600,000	-70,800,000	-108,300,000	-59,000,000	-109,600,000	-58,600,000	-106,276,000	-99,524,000	-93,340,000	-88,760,000	-78,550,000	-84,101,000	-81,800,000	-69,744,000	-50,070,000	-26,818,000	-10,625,000	-62,263,000	-30,366,000	-31,607,000	-43,920,000	-5,932,000	-9,983,000	-13,622,000	-21,745,000	-15,550,000
increase in prepaid expenses and other assets	-230,700,000	-179,500,000	-55,300,000	252,000,000	-526,300,000	-77,900,000	164,300,000	-275,500,000	-3,400,000	-5,500,000	18,700,000	121,200,000	-243,700,000	-44,800,000	76,100,000	-39,000,000	-227,800,000	-50,000,000									32,117,000				-85,122,000	48,959,000	-56,843,000	-20,325,000					-66,253,000				-8,917,000	596,000	-8,548,000	-20,898,000	31,344,000	-32,412,000	-8,037,000	-43,660,000	9,276,000	-51,249,000	-6,156,000	-4,487,000	1,851,000						-2,483,000	-8,611				1,365,000	-12,801,000	-440,000						290,000	-1,206,000	-40,000		-630,000	-765,000	-943,000
increase in deferred revenue	-142,900,000	17,700,000	-21,200,000	43,000,000	89,100,000	116,900,000	43,000,000	45,300,000	-14,500,000	-35,900,000	-59,600,000	-17,700,000	100,200,000	9,500,000	-49,000,000	-6,400,000	78,800,000	-143,600,000	35,800,000	33,400,000	5,000,000	73,900,000	-81,800,000	-25,300,000	-25,400,000	426,500,000				-54,596,000	-53,983,000	-48,461,000	-23,055,000	12,400,000	-37,906,000	216,326,000	-25,355,000	91,205,000	-15,171,000	640,748,000	-545,000	-16,140,000	-10,293,000	-10,443,000	2,731,000	37,107,000									-11,944,000	-10,244,000	-10,310,000	-14,509,000	156,044,000	13,103,000	3,513,000	3,194	-16,603,000	3,327,000	3,200,000	10,210,000	-1,044,000	37,666,000										-8,735,000	-782,000	-25,994,000
increase in accounts payable, accrued expenses, and other liabilities	216,400,000	-214,100,000	225,600,000	194,400,000	204,600,000	110,500,000	-138,700,000	578,600,000	39,700,000	119,000,000	347,600,000	-160,300,000			365,700,000	76,700,000			38,100,000	59,900,000	106,100,000	-85,200,000	324,600,000	9,600,000	129,900,000	-19,600,000	30,148,000	112,873,000	-9,675,000	76,654,000	5,720,000	118,324,000	-334,927,000	187,695,000	146,542,000	-26,487,000	30,494,000	103,431,000	139,005,000	35,314,000	103,804,000	25,534,000	85,730,000	59,686,000	30,959,000	-14,139,000	41,790,000	59,302,000	3,487,000	32,105,000	-18,252,000	-3,558,000	20,079,000	12,710,000									3,052,000	6,218,000	-7,564,000	-6,650,000	14,172,000	152,000	2,101,000				2,756,000			-1,049,000				1,301,000
total adjustments	-247,200,000	236,400,000	345,100,000	-49,400,000	-1,078,300,000	790,500,000	-69,900,000	106,500,000	54,000,000	549,800,000	522,800,000	-686,800,000	-287,700,000	1,128,200,000	143,500,000	1,781,400,000	-2,472,200,000	-446,700,000	81,800,000	-1,096,400,000	46,100,000	73,400,000	-4,600,000	-112,300,000	-4,800,000	435,900,000	-91,522,000	-141,694,000	-156,847,000	140,763,000	393,430,000	26,515,000	-418,314,000	106,970,000	124,764,000	386,225,000	203,281,000	-136,396,000	126,829,000	682,455,000	48,963,000	-163,523,000	88,107,000	83,837,000	235,055,000	-11,916,000	179,975,000	-48,851,000	40,788,000	-12,626,000	-377,222,000	-193,850,000	-155,120,000	-98,692,000	15,630,000	28,455,000	32,867,000	-27,102,000	194,544,000	12,849,000	20,521,000	7,282	-20,431,000	24,656,000	-6,279,000	25,138,000	23,267,000	20,679,000	84,274,000	12,579,000	2,901,000	25,658,000	9,825,000	19,654,000	-1,584,000	37,255,000		7,490,000	32,007,000	-83,114,000
net cash from operating activities	1,144,400,000	1,045,100,000	1,262,800,000	1,291,200,000	354,000,000	1,512,500,000	1,089,700,000	1,114,300,000	1,022,400,000	1,367,600,000	1,719,900,000	628,900,000	564,400,000	2,101,700,000	2,372,500,000	3,413,600,000	626,700,000	668,500,000	1,231,000,000	-254,300,000	943,400,000	698,000,000	787,400,000	557,300,000	188,300,000	897,000,000	728,831,000	452,961,000	394,565,000	618,743,000	566,949,000	414,832,000	-30,570,000	355,901,000	377,879,000	651,029,000	415,148,000	29,340,000	281,823,000	892,853,000	243,606,000	-87,502,000	198,283,000	163,557,000	327,790,000	53,527,000	276,781,000	92,455,000	128,164,000	86,248,000	93,185,000	-2,382,000	-78,377,000	-87,041,000	-46,735,000	-34,050,000	-10,580,000	-41,699,000	160,669,000	-12,625,000	-10,001,000	-10,199	-41,546,000	6,197,000	-17,897,000	-10,700,000	-3,507,000	-9,238,000	53,303,000	-14,831,000	-20,675,000	5,278,000	-19,847,000	-14,998,000	-28,583,000	33,132,000		-3,586,000	17,458,000	-18,582,000
cash flows from investing activities:
purchases of marketable and other securities	-2,855,100,000	-2,539,300,000	-1,952,900,000	-4,591,100,000	-4,415,900,000	-5,657,500,000	-2,131,800,000	-3,243,100,000	-4,521,700,000	-1,749,400,000	-3,142,900,000	-570,100,000	-1,465,100,000	-2,309,800,000	-2,175,800,000	-2,985,800,000	-526,500,000	-1,360,000,000	-598,300,000	-1,109,200,000	-819,200,000	-714,300,000	-367,500,000	-645,800,000	-1,148,900,000	-1,040,200,000	-311,942,000	-352,353,000	-579,892,000	-601,313,000
sales or maturities of marketable and other securities	2,167,900,000	3,458,300,000	2,582,000,000	4,258,600,000	4,054,500,000	4,132,200,000	2,382,900,000	2,997,800,000	2,268,700,000	1,792,800,000	1,537,400,000	1,831,700,000	1,435,100,000	746,300,000	318,000,000	680,200,000	800,800,000	416,300,000	454,700,000
capital expenditures	-219,000,000	-229,300,000	-199,600,000	-241,900,000	-180,500,000	-133,900,000	-251,400,000	-176,000,000	-113,000,000	-178,200,000	-152,200,000	-142,500,000	-153,600,000	-141,800,000	-154,900,000	-133,200,000	-148,500,000	-115,300,000	-161,400,000	-153,200,000	-129,900,000	-170,100,000	-139,000,000	-121,700,000	-94,600,000	-74,300,000	-85,462,000	-106,246,000	-112,017,000	-79,375,000	-107,663,000	-59,653,000	-54,849,000	-50,461,000	-150,455,000	-118,556,000	-138,836,000	-104,094,000	-177,779,000	-146,099,000	-239,893,000	-114,162,000	-117,542,000	-79,769,000	-70,873,000	-64,822,000	-68,976,000	-31,691,000	-34,453,000	-21,203,000	-15,162,000	-10,248,000	-12,872,000	-11,055,000	-8,898,000	-14,864,000	-22,166,000	-32,262,000	-22,103,000	-22,581,000	-22,743,000	-21,917	-9,328,000	-6,742,000	-3,047,000	-4,692,000	-1,827,000	-1,197,000	-1,208,000	-617,000	-340,000	-646,000	-351,000	-1,716,000	-1,538,000	-1,359,000	-1,327,000	-2,314,000	-1,548,000	-985,000	-1,285,000	-3,386,000
free cash flows	925,400,000	815,800,000	1,063,200,000	1,049,300,000	173,500,000	1,378,600,000	838,300,000	938,300,000	909,400,000	1,189,400,000	1,567,700,000	486,400,000	410,800,000	1,959,900,000	2,217,600,000	3,280,400,000	478,200,000	553,200,000	1,069,600,000	-407,500,000	813,500,000	527,900,000	648,400,000	435,600,000	93,700,000	822,700,000	643,369,000	346,715,000	282,548,000	539,368,000	459,286,000	355,179,000	-85,419,000	305,440,000	227,424,000	532,473,000	276,312,000	-74,754,000	104,044,000	746,754,000	3,713,000	-201,664,000	80,741,000	83,788,000	256,917,000	-11,295,000	207,805,000	60,764,000	93,711,000	65,045,000	78,023,000	-12,630,000	-91,249,000	-98,096,000	-55,633,000	-48,914,000	-32,746,000	-73,961,000	138,566,000	-35,206,000	-32,744,000	-32,116	-50,874,000	-545,000	-20,944,000	-15,392,000	-5,334,000	-10,435,000	52,095,000	-15,448,000	-21,015,000	4,632,000	-20,198,000	-16,714,000	-30,121,000	31,773,000		-5,900,000	15,910,000	-19,567,000
payments for intangible assets
proceeds from sale of property, plant, and equipment			0	0
acquisitions, net of cash acquired			-11,500,000	0			-3,800,000
net cash from investing activities			350,600,000	-574,400,000	-557,200,000	-1,687,100,000	-66,200,000	-496,300,000	-2,386,900,000	-235,700,000	-1,857,700,000	192,300,000	-413,900,000	-1,705,300,000	-2,012,700,000	-2,438,800,000	125,800,000	-1,059,000,000	-305,000,000	-775,800,000	1,453,400,000	-443,200,000	-208,700,000	-207,000,000	-836,000,000	-776,100,000	-265,907,000	-286,708,000	-484,973,000	-425,412,000	-335,746,000	-358,884,000	-170,409,000	-140,143,000	-271,356,000	-405,853,000	-326,010,000	-43,685,000	-123,300,000	-283,171,000	-371,649,000	-129,481,000	56,645,000	-123,068,000	-118,123,000	-236,231,000	-109,948,000	-214,452,000	116,630,000	-147,685,000	91,103,000	-48,754,000	-139,188,000	15,766,000	-903,000	142,935,000	20,347,000	-353,774,000	51,004,000	4,595,000	-135,978,000	-39,538	62,777,000	-154,577,000	37,944,000	-1,874,000	-46,200,000	-74,112,000	-163,214,000	66,463,000	-47,484,000	-10,870,000	25,303,000	45,800,000	25,966,000	18,425,000		-13,392,000	-68,988,000	70,230,000
cash flows from financing activities:
proceeds from issuance of common stock	31,500,000	60,600,000	90,900,000	254,700,000	437,600,000	682,100,000	301,000,000	268,600,000	90,700,000	485,200,000	372,600,000	318,500,000	306,800,000	521,600,000	542,700,000	821,400,000	213,200,000	95,000,000	104,100,000	303,100,000	1,356,600,000	811,400,000	48,300,000	8,400,000	14,500,000	140,600,000	27,092,000	53,335,000	20,646,000	13,427,000	13,321,000	38,199,000	172,020,000	16,673,000	36,962,000	26,171,000	24,302,000	39,304,000	55,935,000	34,598,000	39,552,000	76,273,000	45,241,000	17,747,000	8,015,000	55,042,000	15,675,000	7,418,000	21,336,000	12,964,000
payments in connection with common stock tendered for employee tax obligations	-5,600,000	-4,300,000	-253,400,000	-120,200,000	-311,800,000	-343,700,000	-458,100,000	-129,400,000	-16,100,000	-97,000,000	-189,100,000	-108,900,000	-48,900,000	-98,800,000	-582,400,000	-269,600,000	-26,200,000	-154,500,000	-28,300,000	-80,900,000	-416,500,000	-155,100,000	-147,500,000	0	-29,800,000	-10,700,000	-110,104,000	-45,243,000			-223,856,000	-46,395,000			-96,228,000	-1,941,000	-43,971,000	-1,042,000	-88,864,000	-35,743,000	-14,738,000	-21,192,000	-91,718,000	-110,876,000	-1,904,000	-63,086,000	-28,729,000	-93,221,000	-70,052,000	-3,085,000	-91,825,000	-10,031,000	-12,366,000	-49,078,000
repurchases of common stock	-1,061,500,000	-1,041,400,000	-973,000,000	-735,100,000	-603,900,000	-291,300,000	-289,000,000	-546,500,000	-688,800,000	-710,700,000	-431,100,000	-934,600,000	-359,000,000	-358,100,000	-866,900,000	-166,400,000	-305,200,000	-306,900,000	-381,100,000	-92,100,000	-5,052,900,000	-320,700,000	-246,500,000	-19,400,000	0	-10,000,000	-22,000
dividends paid	-92,600,000	-93,800,000
net cash from financing activities	-1,128,200,000	-1,089,200,000	-1,135,500,000	-634,000,000	-478,100,000	47,100,000	-446,100,000	-407,300,000	-614,200,000	-322,500,000	-247,600,000	-725,000,000	-101,100,000	64,700,000	-906,600,000	385,400,000	-118,200,000	-366,400,000	-305,300,000	612,000,000	-2,612,800,000	335,600,000	-345,700,000	-11,000,000	-15,300,000	119,900,000	-83,034,000	3,714,000	-11,207,000	13,427,000	-210,535,000	-8,196,000	133,519,000	60,812,000	-491,679,000	28,675,000	-46,844,000	-190,543,000	-4,008,000	-345,649,000	10,690,000	76,171,000	-252,763,000	5,930,000	-71,390,000	108,954,000	105,564,000	3,533,000	-43,481,000	11,523,000	-73,010,000	-1,809,000	-5,077,000	-17,750,000	-279,000	10,051,000	13,037,000	182,759,000	1,613,000	2,719,000	56,215,000	1,038	1,324,000	-80,366,000	1,903,000	347,000	2,866,000	1,958,000	180,125,000	1,070,000	787,000	3,416,000	2,959,000	90,000	2,000	1,030,000		-808,000	329,000	4,101,000
effect of exchange rate changes on cash, cash equivalents, and restricted cash	400,000	600,000			-300,000	-500,000	200,000	-200,000
net decrease in cash, cash equivalents, and restricted cash				83,600,000
cash, cash equivalents, and restricted cash at beginning of period	0	2,489,000,000	0	0	0	2,737,800,000	0	0	0	3,119,400,000	0	0	0	2,898,100,000	0	0	0	2,207,300,000	0	0	0	1,630,300,000	0	0	0	1,480,200,000	-33,000	0	0	825,233,000
cash, cash equivalents, and restricted cash at end of period	-1,077,400,000	3,093,000,000	477,200,000	83,600,000	-681,600,000	2,609,800,000	577,600,000	210,500,000	-1,979,100,000	3,928,800,000	-385,400,000	96,200,000	49,400,000	3,359,200,000	-546,800,000	1,360,200,000	634,300,000	1,450,400,000	620,700,000	-418,100,000	-216,000,000	2,220,700,000	233,000,000	339,300,000	-663,000,000	1,721,000,000	379,857,000	169,967,000	-101,615,000	1,031,991,000
the accompanying notes are an integral part of the financial statements.
(gains) losses on marketable and other securities		-139,900,000	212,900,000	-134,700,000
other non-cash items		3,200,000	55,400,000	-29,000,000	-3,000,000	100,000	-17,500,000	-11,800,000	8,600,000	20,600,000	169,000,000	60,700,000	54,000,000	84,300,000	304,300,000	71,800,000	308,300,000	-115,700,000	-23,700,000	64,500,000	-258,400,000	82,600,000	-142,500,000	2,500,000	134,500,000	-23,800,000	94,794,000	-27,714,000	-50,787,000	-4,193,000
decrease in accounts receivable		657,800,000				446,800,000			-2,700,000	210,100,000																																																												4,201,000	-1,131,000	25,511,000
payments for libtayo intangible asset		-42,200,000	-67,400,000	0	-30,400,000	-27,900,000	-62,100,000	-23,900,000	-20,900,000	-100,900,000	-100,000,000
net cash from in investing activities		647,500,000
net increase in cash, cash equivalents, and restricted cash		604,000,000				-128,000,000	577,600,000	210,500,000	-1,979,100,000	809,400,000	-385,400,000	96,200,000	49,400,000	461,100,000	-546,800,000	1,360,200,000	634,300,000	-756,900,000			-216,000,000	590,400,000	233,000,000	339,300,000	-663,000,000	240,800,000	379,890,000	169,967,000	-101,615,000	206,758,000
acquired in-process research and development in connection with asset acquisition											0	0
increase in accounts receivable			-117,800,000	-388,900,000			-82,700,000								-584,500,000	1,541,000,000	-2,825,600,000	-58,300,000																																								-10,825,000	12,909,000	-23,338,000	-6,290,000	-12,997	-9,368,000	122,000	-14,640,000	9,510,000	13,154,000	-26,139,000										531,000	34,485,000	-44,353,000
supplemental disclosure of cash flow information
cash paid for interest
cash paid for income taxes
losses on marketable and other securities						196,100,000		127,000,000	30,900,000	166,600,000
losses (gains) on marketable and other securities											-80,600,000	-253,500,000	166,400,000	204,500,000
asset acquisition, net of cash acquired											0	0
proceeds from issuance of long-term debt
proceeds from bridge loan facility																			0	0
repayment of bridge loan facility																			0
deferred taxes												-85,700,000	-156,000,000	-225,000,000	-205,900,000	7,000,000	41,700,000	10,100,000	-42,300,000	-100,000	108,100,000	9,900,000	-20,600,000	15,300,000	-114,600,000	-10,700,000	-106,479,000	-18,034,000	-9,121,000	-6,366,000	427,051,000	-50,505,000	-16,749,000	-40,988,000	-169,751,000	-27,675,000	-82,867,000	-79,785,000	-55,648,000	-6,906,000	-48,181,000	-10,888,000	-16,138,000	-17,923,000	-24,021,000	-8,522,000	-19,289,000	-9,632,000	52,997,000	39,525,000
decrease in accounts payable, accrued expenses, and other liabilities														-250,400,000				-34,700,000																																																					-2,049,000	-3,069,000
non-cash compensation expense															188,400,000	136,900,000	145,500,000	130,900,000	121,500,000	101,200,000	103,500,000	105,800,000	133,500,000	117,100,000	105,800,000	107,900,000	126,748,000	111,435,000	106,795,000	82,422,000	127,133,000	125,097,000	121,258,000	133,789,000	154,558,000	131,379,000	131,691,000	142,250,000	158,392,000	102,641,000	94,257,000	103,759,000	81,454,000	73,864,000	70,512,000	81,408,000	55,182,000	45,744,000	44,443,000	53,030,000	30,772,000	20,535,000	19,606,000	23,244,000	13,364,000	12,396,000	14,801,000	13,566,000	8,790,000	8,707,000	8,834,000	7,654	8,216,000	8,214,000	8,286,000	7,041,000	6,912,000	6,585,000	5,133,000	4,763,000	4,700,000	4,079,000	4,235,000	5,921,000	5,822,000	5,881,000		618,000	628,000	671,000
increase in trade, sanofi, and other accounts receivable
decrease (increase) in prepaid expenses and other assets																													-9,404,000	68,836,000					-11,314,000						-2,032,000	35,874,000															2,286,000	-723,000	1,842,000					2,373,000	1,493,000				-209,000	-263,000	-396,000	1,023,000
proceeds from issuance of long-term debt, net of issuance costs
increase in sanofi, trade, and other accounts receivable																				-1,228,200,000	121,900,000	-169,000,000
decrease in prepaid expenses and other assets																				-17,400,000	-36,300,000	70,100,000			-26,800,000	69,300,000											17,826,000	39,260,000
sales or maturities of marketable securities																					2,402,500,000	441,200,000	297,800,000	560,500,000	407,500,000	338,400,000	131,497,000	181,891,000	206,936,000	255,276,000	165,309,000	107,109,000	153,154,000	119,012,000	82,365,000	89,914,000	41,768,000	60,409,000	61,442,000	72,226,000	113,313,000	80,456,000	259,939,000	60,628,000	73,381,000	82,469,000	58,994,000	11,908,000	252,490,000	54,754,000	178,439,000	88,889,000	96,028,000	75,853,000	107,899,000	158,480,000	58,151,000	46,088,000	92,604,000	73,550,000	64,359,000	82,694	203,734,000	107,344,000	132,509,000	110,020,000	140,457,000	113,262,000	44,450,000	166,457,000	30,975,000	64,317,000	37,566,000	78,202,000	52,295,000	55,385,000		143,824,000	14,729,000	71,215,000
increase in sanofi, bayer, and trade accounts receivable																							-12,200,000	-204,100,000	-150,700,000	-106,100,000	-40,295,000	-163,698,000			-2,891,000	-126,902,000	-94,999,000	-137,928,000	32,252,000	108,099,000	113,250,000	-397,428,000
proceeds in connection with finance lease liabilities
payments in connection with finance lease liabilities
proceeds in connection with capital and facility lease obligations																															0	0	0	57,000,000
payments in connection with capital and facility lease obligations																															0	0	-7,064,000	-12,861,000
repayments of convertible senior notes																																			-244,000	0	-10,911,000	-1,739,000	-20,460,000	-2,006,000	-127,315,000	-16,686,000	-159,514,000	0
payments in connection with reduction of outstanding warrants																																			-401,248,000	0	0	-242,117,000	-50,000,000	-398,956,000	0	-124,531,000	-151,511,000	0
decrease in deferred revenue																												54,776,000																			-7,159,000	-9,236,000	-5,109,000	-6,470,000		-10,936,000	-8,543,000	-9,126,000																-4,440,000	-3,284,000	-4,779,000		-2,550,000	-2,195,000	-4,653,000
decrease (increase) in sanofi, bayer, and trade accounts receivable																														30,408,000
other non-cash charges and expenses																															19,565,000	6,385,000	33,675,000	3,956,000	31,553,000	5,791,000	3,838,000	3,957,000	504,000	15,570,000	11,621,000	6,006,000	17,159,000	6,246,000	2,837,000	3,761,000	7,980,000	-2,613,000	11,149,000	7,174,000	12,756,000	7,920,000	7,510,000	5,863,000	1,289,000	250,000	582,000			-245,000	470,000
excess tax benefit from stock-based compensation																																						15,649,000	99,766,000	56,833,000	93,149,000	155,569,000	105,024,000	99,335,000	126,937,000	117,260,000	119,017,000	89,964,000	5,583,000	2,293,000
net increase in cash and cash equivalents																															20,668,000	47,752,000	-67,460,000	276,570,000	-385,156,000				154,515,000	264,033,000			2,165,000	46,419,000			272,397,000	-118,464,000			111,278,000	-52,945,000	-222,642,000	-89,025,000	-47,917,000	118,936,000	22,804,000		213,286,000			-48,699			21,950,000				70,214,000	52,702,000	-67,372,000	-2,176,000	8,415,000	30,892,000	-2,615,000	52,587,000		-17,786,000	-51,201,000	55,749,000
cash and cash equivalents at beginning of period																															0	0	0	535,203,000	0	0	0	809,102,000	0	0	0	648,719,000	0	0	0	535,608,000	0	0	0	230,276,000	0	0	0	483,610,000	0	0	112,572,000	0	0	0	207,075,000	247,796	0	0	498,925,000	0	0	237,876,000	0	0	0	184,508,000	0	0	0	95,229,000	0	0	0	118,285,000	0	0
cash and cash equivalents at end of period																															20,668,000	47,752,000	-67,460,000	811,773,000	-385,156,000	273,851,000	42,294,000	604,214,000	154,515,000	264,033,000	-117,353,000	507,907,000	2,165,000	46,419,000	138,277,000	461,858,000	272,397,000	-118,464,000	201,313,000	180,362,000	111,278,000	-52,945,000	-222,642,000	394,585,000	-47,917,000	118,936,000	135,376,000	-212,714,000	213,286,000	-5,311,000	117,311,000	199,097	22,555,000	-228,746,000	520,875,000	-12,227,000	-46,841,000	156,484,000	70,214,000	52,702,000	-67,372,000	182,332,000	8,415,000	30,892,000	-2,615,000	147,816,000		-17,786,000	-51,201,000	174,034,000
purchases of marketable securities																																-406,340,000	-268,714,000	-208,694,000	-203,266,000	-377,211,000			-6,963,000	-209,298,000	-245,069,000	-95,775,000	-85,752,000	-103,927,000	-120,631,000	-253,878,000	-99,966,000	-194,669,000	-101,721,000	-180,922,000	-72,140,000	-127,346,000	-222,338,000	-48,569,000	-99,900,000	0	-15,638,000	-363,459,000	-19,497,000	-44,574,000	-177,594,000	-100,315	-131,629,000	-255,129,000	-91,518,000	-107,202,000	-184,830,000	-186,177,000	-204,856,000	-99,377,000	-78,119,000	-74,541,000	-11,912,000	-30,686,000	-24,791,000	-35,601,000		-154,902,000
(payments) proceeds in connection with capital and facility lease obligations
proceeds in connection with facility lease obligations																																																											0	0	47,544,000
(payments) proceeds in connection with facility lease obligations																																					-615,000	-598,000
net decrease in cash and cash equivalents																																					42,294,000	-204,888,000				-140,812,000				-73,750,000				-49,914,000											-89,764,000		22,555,000			-12,227,000	-46,841,000	-81,392,000
loss on extinguishment of debt																																							1,934,000	21,000	15,964,000	942,000	22,682,000	0
increase in sanofi, bayer healthcare, and trade accounts receivable																																							-28,478,000	-44,190,000	-97,690,000	-321,063,000				-92,529,000
proceeds (payments) in connection with facility and capital lease obligations																																							-385,000	-375,000	20,042,000	6,738,000
non-cash interest expense																																									387,000	2,358,000	2,423,000	4,758,000	4,955,000	5,916,000	5,745,000	6,001,000	5,534,000	5,781,000
payments in connection with facility and capital lease obligations																																											-285,000	-276,000	-272,000	-262,000	-399,000	-628,000	-348,000	-649,000	-602,000	-587,000	-514,000	-500,000
decrease (increase) in sanofi, bayer healthcare, and trade accounts receivable																																												-33,330,000
increase in sanofi and trade accounts receivable																																															101,046,000	-116,808,000	-73,378,000	-109,518,000	-91,849,000	-165,891,000	-197,033,000	-135,312,000
purchase of restricted cash and marketable securities
proceeds in connection with issuance of convertible notes, net of debt issuance costs
proceeds in connection with issuance of warrants
payment in connection with purchase of convertible note hedges
the accompanying notes are an integral part of the financial statements
increase in restricted cash and marketable securities																																																		-314,000	-34,000	-49,000	-6,000	-463,000
proceeds in connection with facility lease obligation
net proceeds from issuances of common stock																																																				8,809,000	7,803,000	31,828,000																							819,000
adjustments to reconcile net income to net cash
used in operating activities:
cash flows from operating activities
provided by operating activities
changes in assets and liabilities
increase in accounts payable, accrued expenses,
and other liabilities																																																							-3,323,000	25,003,000	13,574,000	-20,748,000	10,248,000	5,811,000	12,294,000	15,318
cash flows from investing activities
increase in restricted cash																																																							-4,000				0				0
cash flows from financing activities
payments in connection with facility lease obligations																																																							-241,000	-138,000	-89,000		-83,000	-119,000	-555,000
net proceeds from the issuance of common stock																																																							237,000	10,409,000	13,343,000	183,030,000	1,696,000	2,838,000	9,226,000	1,038	2,480,000	1,782,000	1,903,000	347,000	2,866,000	1,958,000
payments in connection with capital lease obligations
used in operating activities
payments in connection with capital lease obligation																																																								-220,000	-217,000
loss on early extinguishment of debt																																																															7,000
net realized gain on marketable securities																																																										51,000
purchases of restricted marketable securities																																																																														-5,538,000	-38,000	-5,500,000
decrease (increase) in restricted cash
repurchases or repayment of notes payable
payments in connection with facility lease obligation
net realized loss on marketable securities
other non-cash expenses
net realized (gain) loss on marketable securities
adjustments to reconcile net income to net cash used in
operating activities
adjustments to reconcile net income to net cash from operating activities
repayment of long-term debt
impairment charge on marketable securities
extinguishment of long-term debt
cumulative effect of a change in accounting principle																																																																					0	0	0	-813,000
decrease in inventory																																																																					70,000	2,245,000						527,000
increase in inventory																																																																								-92,000
forgiveness of loan payable to novartis pharma ag, inclusive of accrued interest																																																																														0	0	-17,770,000
maturities of restricted marketable securities																																																																														5,538,000	5,538,000	5,500,000
repurchase of common stock																																																																													0
borrowings under loan payable																																																																													0	0	0	3,827,000	4,426,000	4,083,000
supplemental disclosure of cash flow information cash paid for interest
net proceeds from the issuance of stock																																																																						1,070,000	397,000	3,416,000		90,000	2,000	1,030,000			329,000	274,000	162,000	45,440,000
non-cash expense related to a license agreement																																																																															334,000	13,000
decrease (increase) in inventory																																																																																188,000
capital lease payments																																																																																	0	0
net proceeds from the issuance of convertible notes
principal payments on note payable

We provide you with 20 years of cash flow statements for Regeneron Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Regeneron Pharmaceuticals stock. Explore the full financial landscape of Regeneron Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Regeneron Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.